ArticleCureus2026
Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE): A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is an interesting phenomenon of drug response characterized by symmetrical, exuberant skin reactions often seen in flexural and intertriginous areas. This report describes a 35-year-old gentleman with no relevant clinical history who developed SDRIFE subsequent to the use of oral fluconazole. His skin examination showed non-scaly, erythematous to violaceous patches within the genital, antecubital, axillary, neck, and inframammary folds. The diagnosis was made based on the clinical picture. Discontinuation of fluconazole and a tapering course of oral prednisolone led to complete resolution of symptoms. This case underlines the importance of maintaining a low threshold of suspicion for rare drug reactions such as SDRIFE, even with medications that are not commonly viewed as requiring dermatological follow-up, so that the condition can be directly managed and hopefully prevented in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.